Search our team at AdventHealth Research Institute
-
NCT06760637
An Interventional, Open-label, Randomized, Multicenter Phase 3 Study of PF-07220060 plus Letrozole Compared to CDK4/6 Inhibitor Plus Letrozole in Participants over 18 Years with Hormone Receptor (HR)-Positive, HER2-Negatrive Advanced/Metastatic Breast Cancer Who Have Not Received Any Prior Systemic Anti-Cancer Treatment for Advanced/Metastatic Disease
This study is currently enrolling.Associated Conditions: Breast CancerResearch Area: Clinical Cancer ResearchResearch Location: Altamonte, FloridaThe purpose of the study is to evaluate whether PF-07220060 plus letrozole can improve clinical outcomes relative to cyclin-dependent kinase (CDK) 4/6 inhibitor (CDK4/6i) (investigator’s choice...
-
NCT06492616
STML-ELA-0422 Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence - A Global, Multicenter, Randomized, Open-label Phase 3 Study (ELEGANT)
This study is currently enrolling.Associated Conditions: Breast CancerResearch Area: Clinical Cancer ResearchResearch Location: Altamonte, FloridaIn this study, we are testing a new endocrine therapy, called elacestrant, that is an endocrine therapy that stops hormones from attaching to cancer cells and helping them grow. Researchers would like...
-
NCT5616104
MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Study)
This study is currently enrolling.Associated Conditions: Breast CancerResearch Area: Clinical Cancer ResearchResearch Location: Altamonte, FloridaThe purpose of this study is to create a large-scale, population-based database. This database will match health information with genome data to potentially identify new gene associations in breast...
-
NCT06401421
Breast Cancer Clinical Validation Study to Predict Recurrence of High-Risk Early Breast Cancer Treated With Neoadjuvant Therapy Using a Bespoke Circulating Tumor DNA Assay to Detect Molecular Residual Disease
This study is currently enrolling.Associated Conditions: Breast CancerResearch Area: Clinical Cancer ResearchResearch Location: Altamonte, FloridaThis study is evaluating a new type of biomarker found in individuals who have cancer. A biomarker is found in blood, other body fluids, or tissues related to traces of cancer remaining after cancer...
-
NCT06312176
An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination with Pembrolizumab Versus Treatment of Physician’s Choice in Participants with HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer
This study is currently enrolling.Associated Conditions: Breast CancerResearch Area: Clinical Cancer ResearchResearch Location: Altamonte, FloridaThis trial is testing MK-2870 given alone and MK-2870 given with pembrolizumab (MK-2870 plus pembro) in people with advanced breast cancer that cannot be surgically removed.
This trial will compare... -
NCT05953337
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC)
This study is currently enrolling.Associated Conditions: Liver CancerResearch Area: Clinical Cancer ResearchResearch Location: Altamonte, FloridaThe purpose of this study is to evaluate the safety and effectiveness of a new medical device and how well it works for people with HCC. The new medical device is called Eye90 microspheres (Eye90)...
-
NCT05563220
STML-ELA-022 A Phase 1b/2, Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer (ELEVATE)
This study is currently enrolling.Associated Conditions: Breast CancerResearch Area: Clinical Cancer ResearchResearch Location: Altamonte, FloridaThis research study is being done to find out if elacestrant is safe and tolerable when given in combination with one of the following study drugs, approved in the treatment of advanced breast cancer...
-
NCT05514054
EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence
This study is currently enrolling.Associated Conditions: Breast CancerResearch Area: Clinical Cancer ResearchResearch Location: Altamonte, FloridaThis study is being done to see how safe an investigational drug is and how well it will work to help people with Estrogen receptor positive (ER+), human epidermal growth factor receptor 2-negative...
-
NCT04852887
A PHASE III CLINICAL TRIAL EVALUATING DE-ESCALATION OF BREAST RADIATION FOR CONSERVATIVE TREATMENT OF STAGE I, HORMONE SENSITIVE, HER2-NEGATIVE,ONCOTYPE RECURRENCE SCORE d 18 BREAST CANCER
This study is currently enrolling.Associated Conditions: Breast CancerResearch Area: Clinical Cancer ResearchResearch Location: Altamonte, FloridaThis study is being done to answer the following question: Is treatment with hormonal therapy as good as the usual treatment of radiation and hormonal therapy in women with low-risk breast cancer who...
-
NCT05840211
A Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Patients with Hormone Receptor-Positive (HR+)/Human Epidermal Growth Factor Receptor 2-Negative (HER2−) (HER2 IHC0 or HER2-low [IHC 1+, IHC 2+/ISH−]) Inoperable, Locally Advanced, or Metastatic Breast Cancer and Have Received Endocrine Therapy ASCENT 07
This study is not currently enrolling.Associated Conditions: Breast CancerResearch Area: Clinical Cancer ResearchResearch Location: Altamonte, FloridaThe purpose of this study is to see if sacituzumab govitecan can improve life spans of patients with HR+/HER2- metastatic breast cancer and their tumor does not grow or spread when compared to current...
-
NCT05629585
D926XC00001: Phase 3, Open-Label, Randomized Study of Datopotamab Deruxtecan with or without Durvalumab Versus Investigator’s Choice of Therapy in Patients with Stage I-III Triple Negative Breast Cancer who have Residual Invasive Disease in Breast and/or Axillary Lymph Nodes Following Neoadjuvant Systemic Therapy and Surgical Resection (TROPION-Breast03)
This study is not currently enrolling.Associated Conditions: Breast CancerResearch Area: Clinical Cancer ResearchResearch Location: Altamonte, FloridaWe are doing this study to learn more about whether an investigational drug called datopotamab deruxtecan (also called Dato-DXd), either alone or in combination with another investigational drug...